Back

The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UK

29 August 2026 (14:30 - 14:40)
Organised by: Logo
Congress Presentation Part of: Lipid lowering in the prevention era: from statins to RNA therapeutics Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
Assistant Professor M. Leening (Rotterdam, NL)
Abstract
Presentation thumbnail
Potent and sustained blood pressure reduction with a novel small interfering RNA targeting hepatic angiotensinogen: results from a first-in-human, randomised, phase 1 study
Doctor M. Yang (Chengdu, CN)
Abstract
Presentation thumbnail
Real-world comparative outcomes of evolocumab versus high-intensity statin for primary prevention
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Reduction in total cardiovascular events with evolocumab in patients with no prior myocardial infarction or stroke: a pre-specified analysis of VESALIUS-CV
Professor J. Nicolau (Sao Paulo, BR)
Abstract
Presentation thumbnail
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials
Doctor S. Saluja (New Delhi, IN)
Abstract

Access the full session

Session thumbnail
Lipid lowering in the prevention era: from statins to RNA therapeutics

The Event

Event poster

ESC Congress 2026

29 August 2026 14:30 CET
You may be interested in
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025
thumbnail
Congress Presentation
Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease
29 August 2020
thumbnail
Congress Presentation
Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
27 August 2022
thumbnail
Congress Presentation
The clinical impact of a novel nurse-led secondary prevention lipid service
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources